BLACKLEDGER Selling Watch: CVNA, NFLX, ABOS
BLACKLEDGER's latest selling watch update tracks CVNA, NFLX, ABOS, UEC, DNN, CRSP from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-06-13T08:00:54.579091+00:00.
- CVNA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NFLX (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- ABOS (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
- UEC (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
- DNN (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
- CRSP (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
- NTLA (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
- COIN (stock): Bear public bias, A-List, public score 7.5/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
CVNA Public Research Bio
Name: Carvana Co.. Market class: stock. Public bias: Bear. Public tier: Extended.
Carvana Co., together with its subsidiaries, operates an e-commerce platform for buying and selling used cars. It provides vehicle acquisition, inspection and reconditioning, online search and shopping experience, financing, complementary products, logistics network and distinctive fulfillment experience, and post-sale customer support services. The company also operates auction sites. Carvana Co. was founded in 2012 and is based in Tempe, Arizona.
- Latest public price/reference: $64.13
- Public market capitalization: $70.31B
- Recent public volume/reference: 9.99M
- One-month public movement: -7.58%
- Sector/category: Consumer Cyclical
Why CVNA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Morgan Stanley updates jaw-dropping Carvana stock price target — TheStreet
- Carvana's Latest Receivables Securitization Looks 'Slightly Less' Favorable, RBC Capital Markets Says — MT Newswires
- Carvana Expands ADESA Digital Auctions With Self Service Wholesale Platform — Simply Wall St.
- Chewy Q1 Earnings Meet Estimates, Sales Beat on Autoship Strength — Zacks
NFLX Public Research Bio
Name: Netflix, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Netflix, Inc. provides entertainment services worldwide. The company offers television (TV) series, documentaries, feature films, games, and live programming across various genres and languages. It also provides members the ability to receive streaming content through a host of internet-connected devices, including TVs, digital video players, TV set-top boxes, and mobile devices. Netflix, Inc. was incorporated in 1997 and is headquartered in Los Gatos, California.
- Latest public price/reference: $80.33
- Public market capitalization: $338.30B
- Recent public volume/reference: 35.08M
- One-month public movement: -5.98%
- Sector/category: Communication Services
Why NFLX Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Does Google Stock Have More Upside? — Trefis
- Paramount’s Deal for Warner Bros. Is Cleared by US DOJ — Bloomberg
- Roku Stock Soars 20%. The Streaming Play Could Be for Sale. — Barrons.com
- The #1 Insider Signal Every Trader Should Know — Zacks
ABOS Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: A-List.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Latest public price/reference: $2.37
- Public market capitalization: $171.18M
- Recent public volume/reference: 411.84K
- One-month public movement: -9.37%
- Sector/category: Healthcare
Why ABOS Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: Moderate Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... — GuruFocus.com
- Acumen Pharmaceuticals Q1 Earnings Call Highlights — MarketBeat
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Zacks
- Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? — Zacks
UEC Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Uranium Energy Corp.. Market class: stock. Public bias: Bear. Public tier: A-List.
Uranium Energy Corp., together with its subsidiaries, engages in exploration, pre-extraction, extraction, and processing of uranium and titanium concentrates properties in the United States, Canada, and the Republic of Paraguay. The company was formerly known as Carlin Gold Inc. and changed its name to Uranium Energy Corp. in January 2005. The company was incorporated in 2003 and is headquartered in Corpus Christi, Texas.
- Latest public price/reference: $11.02
- Public market capitalization: $5.46B
- Recent public volume/reference: 12.49M
- One-month public movement: -17.21%
- Sector/category: Energy
Why UEC Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: Moderate Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Energy Fuels Hits Uranium Output Target in 6 Months, Expands Into Rare Earths — IPO-Edge.com
- Why Uranium Energy (UEC) Is Down 24.8% After Preserving Uranium Inventory Amid Wider Quarterly Loss — Simply Wall St.
- Why Uranium Energy Stock Is Plummeting Again Today — Motley Fool
- Uranium Energy Earnings Miss Estimates in Q3 on Higher Spending — Zacks
DNN Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Denison Mines Corp.. Market class: stock. Public bias: Bear. Public tier: A-List.
Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. It holds 95% interest in its flagship project Wheeler River uranium project located in the Athabasca Basin region in northern Saskatchewan. The company was formerly known as International Uranium Corporation and changed its name to Denison Mines Corp. in December 2006. The company was founded in 1954 and is headquartered in Toronto, Canada.
- Latest public price/reference: $3.065
- Public market capitalization: $2.77B
- Recent public volume/reference: 22.28M
- One-month public movement: -9.45%
- Sector/category: Energy
Why DNN Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: Moderate Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Energy Fuels Hits Uranium Output Target in 6 Months, Expands Into Rare Earths — IPO-Edge.com
- Assessing Denison Mines (TSX:DML) Valuation After Phoenix Uranium Project Clears Key Regulatory Milestone — Simply Wall St.
- Uranium Production Milestone Underscores Why Denison Mines Corp. (DNN) Is a Top Penny Stock to Buy — Insider Monkey
- Is Denison Mines (DNN) One of the Best Nuclear Power Stocks to Buy According to Wall Street Analysts? — Insider Monkey
CRSP Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: CRISPR Therapeutics AG. Market class: stock. Public bias: Bear. Public tier: A-List.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemog
- Latest public price/reference: $49.78
- Public market capitalization: $4.90B
- Recent public volume/reference: 1.15M
- One-month public movement: -8.37%
- Sector/category: Healthcare
Why CRSP Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: Moderate Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- CRISPR Therapeutics Expands Funding Capacity As Gene Editing Pipeline Advances — Simply Wall St.
- CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts — Zacks
- CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know — Zacks
- CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? — Motley Fool
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.